诺卡硫霉素，来自诺卡氏菌属的新型噻唑基肽类抗生素。I. 分类学、发酵及生物活性

Nocathiacins, new thiazolyl peptide antibiotics from Nocardia sp. I. Taxonomy, fermentation and biological activities.

作者信息

Li Wenying, Leet John E, Ax Helen A, Gustavson Donald R, Brown Daniel M, Turner Laura, Brown Kimberly, Clark Junius, Yang Hyekyung, Fung-Tomc Joan, Lam Kin S

机构信息

Bristol-Myers Squibb Pharmaceutical Research Institute, 5 Research Parkway, Wallingford, Connecticut 06492, USA.

出版信息

J Antibiot (Tokyo). 2003 Mar;56(3):226-31. doi: 10.7164/antibiotics.56.226.

DOI:10.7164/antibiotics.56.226

PMID:12760678

Abstract

Thiazolyl peptide antibiotics, nocathiacin I, II and III, were identified in a culture of Nocardia sp. WW-12651 (ATCC 202099). They exhibit potent in vitro activity (ng/ml) against a wide spectrum of gram-positive bacteria, including multiple-drug resistant pathogens such as methicillin-resistant Staphylococcus aureus (MRSA), multi-drug resistant Enterococcus faecium (MREF) and fully penicillin-resistant Streptococcus pneumoniae (PRSP), and demonstrate excellent in vivo efficacy in a systemic Staphylococcus aureus infection mice model.

摘要

噻唑基肽类抗生素诺卡硫霉素I、II和III是在诺卡氏菌属WW - 12651（ATCC 202099）的培养物中鉴定出来的。它们在体外对多种革兰氏阳性菌表现出强效活性（纳克/毫升），包括耐多药病原体，如耐甲氧西林金黄色葡萄球菌（MRSA）、耐多药粪肠球菌（MREF）和对青霉素完全耐药的肺炎链球菌（PRSP），并且在全身性金黄色葡萄球菌感染小鼠模型中显示出优异的体内疗效。